Abstract

Small diameter (<6 mm) vessel grafts still pose a challenge for scientists worldwide. Decellularised umbilical artery (dUA) remains promising as small diameter tissue engineered vascular graft (TEVG), yet their immunogenicity remains unknown. Herein, we evaluated the host immune responses, with a focus on the innate part, towards human dUA implantation in mice, and confirmed our findings in an ex vivo allogeneic human setup. Overall, we did not observe any differences in the number of circulating white blood cells nor the number of monocytes among three groups of mice (1) dUA patch; (2) Sham; and (3) Mock throughout the study (day −7 to 28). Likewise, we found no difference in systemic inflammatory and anti-inflammatory cytokine levels between groups. However, a massive local remodelling response with M2 macrophages were observed in the dUA at day 28, whereas M1 macrophages were less frequent. Moreover, human monocytes from allogeneic individuals were differentiated into macrophages and exposed to lyophilised dUA to maximize an eventual M1 response. Yet, dUA did not elicit any immediate M1 response as determined by the absence of CCR7 and CXCL10. Together this suggests that human dUA elicits a minimal pro-inflammatory response further supporting its use as a TEVG in an allogeneic setup.

Highlights

  • IntroductionCardiovascular diseases (CVDs) are one of the heaviest health burdens globally

  • Very limited knowledge exists on immune responses directed against materials used for tissue engineered vascular graft (TEVG) generation and in particular natural scaffolds, such as decellularised tissues

  • We tested the innate immune response against human Decellularised umbilical artery (dUA) and found no major adverse effects. This further supports the future use of dUAs in producing TEVGs for human vascular bypass surgery in patients with limited autologous grafts available

Read more

Summary

Introduction

Cardiovascular diseases (CVDs) are one of the heaviest health burdens globally. 18 million people died from CVDs in 2016, and about half of them died due to ischemic heart disease (IHD), making it the leading cause of death worldwide [1]. For more than 50 years, scientists have worked on developing tissue engineered vascular grafts (TEVGs), and large diameter (>6 mm) TEVGs are nowadays successfully used for vascular bypass surgery. Small diameter (

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call